{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:07:27Z","timestamp":1785528447829,"version":"3.56.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017415","name":"Peking University First Hospital","doi-asserted-by":"publisher","award":["2021-513"],"award-info":[{"award-number":["2021-513"]}],"id":[{"id":"10.13039\/100017415","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clgc.2024.102216","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T02:43:56Z","timestamp":1725417836000},"page":"102216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Outcomes of Radical Radiotherapy for the Treatment of Localized Renal Pelvic and Ureteral Carcinoma Intolerant to Surgery: A Real-World Study"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2430-6517","authenticated-orcid":false,"given":"Ming-Zhu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Shu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Wei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Ying","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Song","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clgc.2024.102216_bib0001","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.clgc.2024.102216_bib0002","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","article-title":"European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 update","volume":"79","author":"Roupr\u00eat","year":"2021","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.clgc.2024.102216_bib0003","first-page":"9699","article-title":"Outcomes of upper tract urothelial cancer managed non-surgically","volume":"26","author":"Syed","year":"2019","journal-title":"Can J Urol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102216_bib0004","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/bju.14042","article-title":"Survival outcomes for patients with localised upper tract urothelial carcinoma managed with non-definitive treatment","volume":"121","author":"Syed","year":"2018","journal-title":"BJU international"},{"issue":"1","key":"10.1016\/j.clgc.2024.102216_bib0005","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clon.2020.07.008","article-title":"Stereotactic body radiation therapy in the management of oligometastatic and oligoprogressive bladder cancer and other urothelial malignancies","volume":"33","author":"Franzese","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"6","key":"10.1016\/j.clgc.2024.102216_bib0006","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.clgc.2017.04.007","article-title":"Consolidative radiotherapy in metastatic urothelial cancer","volume":"15","author":"Shah","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2024.102216_bib0007","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1016\/j.clgc.2016.01.004","article-title":"Consolidation with radiation or concurrent chemo-radiation after chemotherapy results in durable complete remissions of isolated nodal recurrences of urothelial cancer: a case series and review","volume":"14","author":"Al-Marrawi","year":"2016","journal-title":"Clin Genitourin Cancer"},{"issue":"3 Suppl","key":"10.1016\/j.clgc.2024.102216_bib0008","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ijrobp.2009.09.040","article-title":"Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues","volume":"76","author":"Bentzen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.clgc.2024.102216_bib0009","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.clgc.2024.102216_bib0010","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S1470-2045(20)30147-9","article-title":"Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial","volume":"21","author":"Kleinmann","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102216_bib0011","doi-asserted-by":"crossref","first-page":"114","DOI":"10.23736\/S2724-6051.20.03689-9","article-title":"Thulium-laser retrograde intra renal ablation of upper urinary tract transitional cell carcinoma: an ESUT Study","volume":"73","author":"Bozzini","year":"2021","journal-title":"Minerva Urol Nephrol"},{"key":"10.1016\/j.clgc.2024.102216_bib0012","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.euros.2022.10.010","article-title":"Effectiveness and safety of thulium fiber laser in the conservative management of patients with upper tract urothelial carcinoma","volume":"46","author":"Proietti","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.clgc.2024.102216_bib0013","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.euros.2023.11.005","article-title":"Current evidence on utility, outcomes, and limitations of endoscopic laser ablation for localized upper urinary tract urothelial carcinoma: results from a scoping review","volume":"59","author":"Giulioni","year":"2024","journal-title":"Eur Urol Open Sci"},{"issue":"7","key":"10.1016\/j.clgc.2024.102216_bib0014","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.21037\/tau-21-291","article-title":"Radiation therapy for nonmetastatic medically inoperable upper-tract urothelial carcinoma","volume":"10","author":"Liu","year":"2021","journal-title":"Transl Androl Urol"},{"issue":"7","key":"10.1016\/j.clgc.2024.102216_bib0015","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1464-410X.2010.09675.x","article-title":"Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005","volume":"107","author":"Raman","year":"2011","journal-title":"BJU international"},{"issue":"1","key":"10.1016\/j.clgc.2024.102216_bib0016","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/j.prro.2021.07.006","article-title":"Stereotactic ablative radiation therapy for the treatment of upper urinary tract urothelial carcinoma","volume":"12","author":"Khriguian","year":"2022","journal-title":"Pract Radiat Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2024.102216_bib0017","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cncr.24135","article-title":"Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration","volume":"115","author":"Margulis","year":"2009","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.clgc.2024.102216_bib0018","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1016\/j.ejca.2009.06.016","article-title":"Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients","volume":"45","author":"Lughezzani","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2024.102216_bib0019","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2012.02.030","article-title":"Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature","volume":"62","author":"Lughezzani","year":"2012","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102216_bib0020","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.juro.2012.10.057","article-title":"Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis","volume":"189","author":"Roupr\u00eat","year":"2013","journal-title":"Urol J"},{"issue":"10232","key":"10.1016\/j.clgc.2024.102216_bib0021","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clgc.2024.102216_bib0022","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00345-023-04701-8","article-title":"Safety and efficacy of radiotherapy combined with chemotherapy for recurrent metastatic renal pelvic and ureteral carcinoma","volume":"42","author":"Liu","year":"2024","journal-title":"World J Urol"},{"issue":"11","key":"10.1016\/j.clgc.2024.102216_bib0023","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10064","key":"10.1016\/j.clgc.2024.102216_bib0024","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.clgc.2024.102216_bib0025","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1200\/JCO.19.01213","article-title":"Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer","volume":"38","author":"Vuky","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102216_bib0026","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s00345-020-03440-4","article-title":"Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response","volume":"39","author":"Daro-Faye","year":"2021","journal-title":"World J Urol"},{"issue":"12","key":"10.1016\/j.clgc.2024.102216_bib0027","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s10147-023-02421-y","article-title":"Current trends in the promising immune checkpoint inhibition and radiotherapy combination for locally advanced and metastatic urothelial carcinoma","volume":"28","author":"Sano","year":"2023","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102216_bib0028","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.eururo.2019.01.009","article-title":"Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma","volume":"75","author":"Sundahl","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102216_bib0029","article-title":"Stereotactic body radiotherapy for localized ureter transitional cell carcinoma: three case reports","volume":"2015","author":"Maehata","year":"2015","journal-title":"Urol Case Rep"},{"issue":"1","key":"10.1016\/j.clgc.2024.102216_bib0030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.adro.2017.08.012","article-title":"Stereotactic body radiation therapy for medically inoperable, clinically localized, urothelial carcinoma of the renal pelvis: a case report","volume":"3","author":"Evans","year":"2018","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102216_bib0031","first-page":"24","article-title":"Proton beam therapy for renal pelvis and ureter cancer: a report of 5 cases and a literature review","volume":"11","author":"Iizumi","year":"2019","journal-title":"Mol Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:39:57Z","timestamp":1778618397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324001861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1558767324001861"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102216","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Radical Radiotherapy for the Treatment of Localized Renal Pelvic and Ureteral Carcinoma Intolerant to Surgery: A Real-World Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102216","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102216"}}